**Abstract**

**Specific objective of the study**: Assessment of the current prescription trends and psychopharmacotherapeutical options for Major Depressive Disorder (MDD) applied in tertiary psychiatric treatment centers throughout Europe.

**Methods:** This international multicenter (9 academic sites in 8 European countries), cross-sectional study applied retrospective evaluation of treatment response in 1181 adult in- and outpatients suffering from MDD. The thorough clinical assessment included evaluation of socio-demographic, clinical, and medication data, as well as the present symptom severity, which was measured by the Montgomery and Åsberg Depression Rating Scale (MADRS). The clinical improvement in the course of the present major depressive episode (MDE) was quantified according to retrospective MADRS measurements. Epidemiological data were analyzed using descriptive statistics. In order to determine the influence of symptom severity and treatment response on the prescription patterns analyses of variance (ANOVA) and Spearman correlation analyses were applied.

**Summary of results:** Selective serotonin reuptake inhibitors (SSRIs) were administered in 53.4% of all MDD patients as a first-line treatment, followed by serotonin-norepinephrine reuptake inhibitors (SNRIs) in 23.6% of all MDD patients. Polypharmacy was applied in 59.4% of all MDD patients, whereby the median represented 2 psychiatric compounds per patient. Furthermore, a significant correlation was detected for the number of individual drugs with the current MADRS total score and the MADRS total score change in the course of the present MDE. Concerning the most frequently prescribed adjunctive agents, benzodiazepines were administered in 33.2% of all MDD patients, followed by antidepressants in 29.0%, antipsychotics in 24.2%, and mood stabilizers in 10.1% of all participants. No significant differences were found between the different psychopharmacological classes used as augmentation strategies with regard to symptom severity and treatment response.

**Conclusion reached:** This multicenter, retrospective, cross-sectional study covers the widespread use of psychopharmacotherapeutical options for MDD assessed in tertiary psychiatric treatment centers in Europe.
